These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 27559851)
21. YM155 induces EGFR suppression in pancreatic cancer cells. Na YS; Yang SJ; Kim SM; Jung KA; Moon JH; Shin JS; Yoon DH; Hong YS; Ryu MH; Lee JL; Lee JS; Kim TW PLoS One; 2012; 7(6):e38625. PubMed ID: 22723871 [TBL] [Abstract][Full Text] [Related]
22. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia. Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731 [TBL] [Abstract][Full Text] [Related]
23. Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues. Cheng XJ; Lin JC; Ding YF; Zhu L; Ye J; Tu SP Oncotarget; 2016 Feb; 7(6):7096-109. PubMed ID: 26771139 [TBL] [Abstract][Full Text] [Related]
24. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells. Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458 [TBL] [Abstract][Full Text] [Related]
25. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125 [TBL] [Abstract][Full Text] [Related]
26. Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. Chuwa AH; Sone K; Oda K; Ikeda Y; Fukuda T; Wada-Hiraike O; Inaba K; Makii C; Takeuchi M; Oki S; Miyasaka A; Kashiyama T; Arimoto T; Kuramoto H; Kawana K; Yano T; Osuga Y; Fujii T Gynecol Oncol; 2016 Jun; 141(3):564-569. PubMed ID: 27079211 [TBL] [Abstract][Full Text] [Related]
27. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Kita A; Nakahara T; Yamanaka K; Nakano K; Nakata M; Mori M; Kaneko N; Koutoku H; Izumisawa N; Sasamata M Leuk Res; 2011 Jun; 35(6):787-92. PubMed ID: 21237508 [TBL] [Abstract][Full Text] [Related]
28. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Feng W; Yoshida A; Ueda T Biochem Biophys Res Commun; 2013 May; 435(1):52-7. PubMed ID: 23618862 [TBL] [Abstract][Full Text] [Related]
31. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582 [TBL] [Abstract][Full Text] [Related]
32. The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Yoon DH; Shin JS; Jin DH; Hong SW; Jung KA; Kim SM; Hong YS; Kim KP; Lee JL; Suh C; Lee JS; Kim TW Anticancer Res; 2012 May; 32(5):1681-8. PubMed ID: 22593446 [TBL] [Abstract][Full Text] [Related]
33. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848 [TBL] [Abstract][Full Text] [Related]
34. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712 [TBL] [Abstract][Full Text] [Related]
35. Commitment toward cell death by activation of autophagy with survivin inhibitor YM155 in two canine squamous cell carcinoma cell lines with high expression of survivin. Miyamoto R; Tani H; Ikeda T; Saima H; Tamura K; Bonkobara M Res Vet Sci; 2021 Mar; 135():412-415. PubMed ID: 33160684 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells. Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644 [TBL] [Abstract][Full Text] [Related]
37. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082 [TBL] [Abstract][Full Text] [Related]
38. YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo. Zhang Z; Ma L; Wang J Oncol Rep; 2015 Aug; 34(2):1074-80. PubMed ID: 26081496 [TBL] [Abstract][Full Text] [Related]
39. Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K⁺ channels. Zhang S; Liu B; Fan Z; Wang D; Liu Y; Li J; Wang N; Liu Y; Zhang B Mol Med Rep; 2016 Apr; 13(4):3415-22. PubMed ID: 26957114 [TBL] [Abstract][Full Text] [Related]
40. YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells. Sasaki R; Ito S; Asahi M; Ishida Y Leuk Res; 2015 Dec; 39(12):1473-9. PubMed ID: 26547260 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]